Share on StockTwits

Hospira (NYSE:HSP) CFO Thomas E. Werner sold 10,000 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $50.82, for a total value of $508,200.00. Following the sale, the chief financial officer now directly owns 54,614 shares of the company’s stock, valued at approximately $2,775,483. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Hospira (NYSE:HSP) traded down 0.25% during mid-day trading on Tuesday, hitting $50.88. 696,415 shares of the company’s stock traded hands. Hospira has a 1-year low of $34.09 and a 1-year high of $52.86. The stock has a 50-day moving average of $48.3 and a 200-day moving average of $44.02. The company has a market cap of $8.504 billion and a price-to-earnings ratio of 62.82.

Hospira (NYSE:HSP) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.60 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.49 by $0.11. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the company posted $0.52 earnings per share. Hospira’s revenue was up 6.3% compared to the same quarter last year. On average, analysts predict that Hospira will post $2.19 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on HSP shares. Analysts at Wells Fargo & Co. initiated coverage on shares of Hospira in a research note on Wednesday, June 11th. They set a “market perform” rating on the stock. Separately, analysts at Zacks upgraded shares of Hospira from a “neutral” rating to an “outperform” rating in a research note on Thursday, May 29th. They now have a $58.00 price target on the stock. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of Hospira in a research note on Thursday, May 1st. They now have a $48.00 price target on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Hospira presently has an average rating of “Hold” and an average target price of $44.29.

Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.